Clinical Trial Update: Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating a third dose of Moderna COVID-19 vaccine in transplant recipients with impaired vaccine response and immune suppression has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immunosuppression-related Vulnerability
• Vaccine Response Impairment

Drugs mentioned

• Moderna COVID-19 vaccine (SARS-CoV-2 vaccine, mRNA-1273)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Vaccine Response Impaired, Immune Suppression | Phase 4 | Status: COMPLETED